Background: The role of vascular invasion (VI) as a prognostic marker in thyroid cancer is continuously debated among investigators. In this systematic review and meta-analysis, we aimed to investigate the association of VI with tumor recurrence and patient mortality in differentiated thyroid cancers (DTCs). Methods: We searched five electronic databases for cases of DTC matching our criteria. Data of tumor persistence, locoregional recurrence (LRR), distant recurrence (DR) and overall recurrence/persistence (RP) were extracted and pooled into odds ratios (OR) and corresponding 95% confidence intervals (CIs) using random effect model. Pooled hazard ratio (HR) for disease-specific survival (DSS) was calculated using random effect model weighted by inverse variance method. Publication bias was examined by using Egger's test and funnel plot. Results: From 1650 studies, we included 26 studies comprising 11 961 DTCs for meta-analyses. In DTC patients, we found significant associations of VI with tumor persistence (OR = 2.75; 95% CI = 1.46-5.18), LRR (OR = 4.44; 95% CI = 2.94-6.71), DR (OR = 5.08; 95% CI = 2.95-8.75), overall RP (OR = 3.53; 95% CI = 2.09-5.96) and worse DSS (HR = 2.47; 95% CI = 1. 45-4.21). Our results also demonstrated that the presence of extensive VI is associated with a significantly higher risk for DR in follicular thyroid carcinomas as compared with focal VI. Conclusion: Our study demonstrated a significant impact of VI on tumor recurrence and patient survival in DTC patients. The presence and extent of VI should be considered an adverse prognostic factor in DTCs.
Introduction
Thyroid carcinoma is the most common endocrine malignancy, and its incidence has been increasing over the years worldwide (1, 2) . According to the World Health Organization (WHO) classification, thyroid cancer is classified into differentiated thyroid carcinoma (DTC), poorly differentiated thyroid carcinoma (PDTC) and undifferentiated thyroid carcinoma (UTC) (3) . DTCs including papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC) and Hurthle cell carcinoma (HCC) account for 95% of thyroid cancer and have more favorable prognosis as compared with PDTCs and ATCs (3) .
DTCs usually exhibit indolent behavior with a 10-year survival rate of approximately 90-95% (1, 3, 4) . Various clinicopathological factors have been reported to affect the patient outcomes such as older age, male gender, large tumor size, nodal or distant metastasis (5) . VI is not a common event in DTCs which ranged from 2.5% to 52% (6, 7, 8) . The rate of VI is higher in FTC than in PTC which can explain why FTC metastasizes to distant organs more frequently than does PTC (7) . The role of VI as a prognostic factor in DTC, however, remains controversial among literature studies (7, 9, 10) .
In the current study, we aimed to conduct a systematic review and meta-analysis of observational studies to determine the impact of VI on tumor recurrence and disease-related mortality in patients with DTC.
Methods

Literature search
We searched for relevant articles in five electronic databases including PubMed, ISI Web of Science, Scopus, World Health Organization Global Health Library (WHO GHL) and Virtual Health Library (VHL) from inception to February 2017. The search terms were the following: (papillary OR follicular OR Hurthle OR differentiated OR well-differentiated) AND thyroid AND (carcinoma OR cancer) AND (vascular OR intravascular OR angioinvasive). Potential studies were also found by reviewing the citations within the included publications and reviews. Our study strictly followed the recommendation of Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement (11) .
Selection criteria and abstract screening
We imported all search results from five electronic databases into Endnote (Thomson Reuters, PA, USA) and performed duplicate deletion. Two reviewers independently screened the titles and abstracts of included studies using the following inclusion criteria (i) retrospective or prospective observational studies and (ii) articles in which the authors investigated the association of VI with tumor RP or disease-related mortality in patients with DTC. We used the following criteria to exclude studies: (i) studies only reporting data on lymphatic invasion and had no data for VI, (ii) articles in which PDTCs or ATCs were included and extracted data of DTC not separately segregatable, (iii) review, (iv) case report, (v) conference, poster, proceeding paper, book, thesis and (vi) duplicated articles. Disagreements between two reviewers were resolved by discussion and consensus.
Full-text screening and data extraction
Full text of all potential articles was consecutively downloaded and screened independently by two reviewers. Relevant data were extracted into a predefined data extraction form. We extracted the following data: institution, city, country, publication year, surgical time period, study design, number of events of tumor recurrence (LRR, DR, tumor persistence, overall RP) and disease-related death. Data of survival outcomes (DSS) and follow-up duration were also collected, if available. Disagreements between two reviewers were resolved again by discussion and consensus. In cases of insufficient data in the original papers or unpublished data, we tried to obtain potential data by contacting the authors via email.
Quality assessment and risk of bias analysis
We assessed the methodologic quality of included studies based on the Newcastle-Ottawa Scale (NOS) for quality of cohort studies in our meta-analyses (12) . Stars were awarded for each cohort study (maximum nine stars) based on a developed checklist (12) . In the second domain of outcome category, we awarded one star if the study had a median time of follow-up longer than five years, which was considered long enough for tumor recurrence and mortality to occur. In the last domain of outcome category, studies with the follow-up rate ≥80% or description of those lost suggesting no difference from those followed were awarded one star. Studies awarded at least six stars were considered moderate-to high-quality studies and those with a NOS value of less than six were regarded low-quality studies.
Data analysis
We used Review Manager version 5.3 (Cochrane Collaborative, Oxford, UK) to analyze data. We calculated the pooled estimates of OR and its 95% CI to examine the association of vascular invasion with tumor recurrence (LRR, DR, tumor persistence and overall RP) by using random-effect modeling. We excluded the studies from the meta-analyses where there were no events in both arms because such studies do not provide any indication of either the direction or magnitude of the effect (13) . Because survival rates at specific time points are known to be incompatible for meta-analyses of time-to-event data, pooled hazard ratio (HR) for DSS was calculated using the random model effect weighted by inverse variance method. HR and its 95% CI were directly collected from the original articles or indirectly estimated from Kaplan-Meier curves using the methods by Tierney et al. (14) Heterogeneity across studies was quantified by (38) , respectively. We decided to select the study with higher number of cases for statistical analysis. Table 1 shows the detailed characteristics of each study. For studies containing potential data, we contacted the authors via email to provide unreported HR and its 95% CI for effects of VI on DSS and we received responses from Sweden, USA and Japan with adequate information for the meta-analysis (32, 33, 38) . Stenson et al. (32) and Sugino et al. (33) provided unadjusted HR and its 95% CI of VI on DSS from their FTC series. We received data of unadjusted HR and its 95% CI of VI on DSS in the study by Xu et al. (38) for the entire DTC population and subgroups of PTC and FTC.
Impact of VI on tumor persistence
We found separate data of tumor persistence in four of included studies, comprising 705 patients with DTCs. The pooled result demonstrated that VI was significantly associated with higher risk for tumor persistence (OR = 2.75; 95% CI = 1.46-5.18) ( Fig. 2A ). There was no heterogeneity across studies (I 2 = 0%; p-heterogeneity = 0.97).
Impact of VI on LRR
Separate data regarding impact of VI on LRR were found in ten studies, including 5018 patients with DTCs. In total, 15.6% DTC patients with VI and 2.7% of DTC patients without VI developed LRR during follow-up. DTCs with VI were associated with a significantly increased risk for LRR (OR = 4.44; 95% CI = 2.94-6.71) (Fig. 2B) . Heterogeneity among included studies was not present (I 2 = 0%; p-heterogeneity = 0.60).
Impact of VI on DR
Ten studies comprising 1949 patients with DTCs provided relevant data regarding association of VI and DR. DR was identified in 13.9% and 2.2% of DTCs with and without VI during follow-up, respectively. The overall estimate showed a significant impact of VI on DR (OR = 5.08; 95% CI = 2.95-8.75) (Fig. 2C ). Amount of heterogeneity among studies was low (I 2 = 15%; p-heterogeneity = 0.30).
Excluding the study by Xu et al. (38) completely removed the heterogeneity among the included studies (I 2 = 0%) 
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Impact of VI on overall RP
We found 14 studies with 8053 DTC patients reporting relevant information of the association of VI and overall RP. The pooled estimate demonstrated that VI significantly increased the risk for overall RP (OR = 3.53; 95% CI = 2.09-5.96) (Fig. 2D) . The degree of heterogeneity across studies was high (I 2 = 60%; p-heterogeneity <0.0001). It remained significant after removing each of included studies at a time but the statistical significance of effects was unaffected. The significant between-study heterogeneity p-heterogeneity = 0.59) and the overall effect slightly decreased but remained significant (OR = 2.11; 95% CI = 1.49-3.00).
Impact of VI on DSS
In 26 included studies, we found relevant data of HR for DSS or sufficient data to estimate HR for DSS in only four studies (5, 8, 36, 37) . We received three replies from USA, Sweden and Japan containing adequate data on unadjusted HR for DSS for the pooled analysis (32, 33, 38) . We used random effect model weighted by inverse variance method to pool HR for DSS and the pooled result demonstrated that VI significantly increased the risk of disease-related mortality in DTC patients with VI compared with DTC patients without VI (HR = 2.47; 95% CI = 1.45-4.21) (Fig. 2E ). There was a moderate amount of heterogeneity between the included studies (I 2 = 45%; p-heterogeneity = 0.09). After excluding the study by Stenson et al. (32) , there was no heterogeneity among the studies (I 2 = 0%; p-heterogeneity = 0.42) and the pooled estimate remained significant with an increased effect size (HR = 3.02; 95% CI = 1.94-4.68).
Subgroup analyses
To further explore the sources of heterogeneity among studies, we performed subgroup analysis with regard to the impact of VI on recurrence and survival in PTC and FTC subgroup. Association of LRR, DR and overall RP with VI in each subgroup is summarized in Table 2 . In PTCs, the pooled results showed that VI significantly increased the risk of LRR, DR and overall RP. However, VI was not associated with a higher risk for tumor persistence (Table 2 and Supplementary Fig. 1 , see section on supplementary data given at the end of this article). In FTC subgroup, effects of VI on tumor persistence, LRR, DR and overall RP were all associated with a significantly increased risk (Table 2 and Supplementary Fig. 2) .
We carried out an additional analysis to further examine the prognostic effect of extensive VI (≥4 VI foci) in FTCs and found eligible data in four studies (9, 27, 28, 38) . Our results demonstrated that the presence of extensive VI increases the risk for DR 26 times as compared with FTCs with focal VI (<4 VI foci) (OR = 26.38; 95% CI = 7.67-90.78; I 2 = 54%). 
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Subgroup analyses for DSS were also performed by HR calculation method (unadjusted HR and adjusted HR) and histologic type (PTC, entire FTC population and minimally invasive FTC (MIFTC)). Subgroups of unadjusted and adjusted HR both showed significantly adverse effects of VI on DSS (Table 3) . When histologically dividing into subgroups of PTC and FTC, only the pooled result of PTC was associated with worse impact on DSS. On the other hand, in subgroups of FTC and MIFTC, VI showed no significant effect on DSS (Table 3 and Supplementary Fig. 3 ). Between-study heterogeneity significantly decreased and was almost absent in subgroup analyses.
Risk of bias assessment and quality of studies
All included studies were retrospective studies. The number of stars awarded to each of included studies ranged from five to eight stars. All studies but two were considered to be of moderate to high quality. Details of given stars within domains of Selection, Comparability and Outcome for all included studies were described in Table 4 .
Publication bias
Egger's regression test and funnel plot were used to examine the presence of publication bias. Observation of funnel plots did not reveal strong indication of publication bias among the set of studies included in the meta-analyses. Egger's regression test of all effects did not suggest any evidence of publication bias (data not shown). We did not analyze publication bias among subgroups because this methods is known to be unreliable for meta-analyses of small numbers of included studies (39) .
Discussion
DTC is the major histologic type and accounts for more than 95% of thyroid cancer (3). Most of DTCs generally show good response to initial treatment. However, a subset of DTCs behave aggressively, develop metastases or recurrence and are associated with a higher rate of mortality. There have been a number of studies investigating the prognostic factors for DTCs, and some factors have been proposed as adverse prognostic factors such as age over 45, tumor size exceeding 4 cm, the presence of extrathyroidal extension, lymph node metastasis and distant metastasis (5, 40, 41) . The role of VI to predict adverse outcome in DTC has been an ongoing debate (5, 8, 32, 38, 40, 41) . Our study is the first meta-analysis to help clarify this debate and confirm the prognostic implication of VI in DTCs.
In our study, we comprehensively reviewed five electronic databases and investigated the association of VI with DTC patient outcomes. Our results demonstrate that the presence of VI in DTCs is not only associated with an increased risk for tumor recurrence or persistence but also significantly associated with an adverse impact on patient DSS. Our findings strongly support the latest ATA guidelines in which DTCs with VI are classified (42) . However, the three-tiered ATA classification did not specifically address the risk of tumor recurrence associated with each histologic type. In subgroup analysis of our meta-analysis, the presence of VI is both associated with a significantly increased risk for LRR, DR and overall RP in both PTC and FTC patients ( Table 2) . As a result, pathologists should assess the presence and extent of VI in all specimen blocks during histopathological examination because the presence of even one focus of VI can enhance the recurrence risk for patients and influence the management and follow-up schedule. The risk for tumor persistence is heterogeneous between histologic subgroups with the insignificant pooled results in patients with PTC. But, this result should be interpreted with caution because of the small number of included studies and patients (Table 2 ). In addition to the presence of VI, the extent of VI (number of VI foci) also merits concern from thyroid specialists. A few studies reported that FTCs with a greater extent of VI (≥4 foci of VI) are associated with poorer outcome (24, 38, 43) . Our results demonstrated that FTCs with extensive VI (≥4 VI foci) are associated with a significantly increased risk for distant metastasis during follow-up as compared to tumors with focal VI (<4 foci). In the ATA 2009 guidelines, the degree of VI in FTC was not included in the risk stratification system (44) . But, this prognostic variable was supplemented in the ATA 2015 guidelines in which FTCs with extensive VI (≥4 VI foci) are classified as ATA high risk (42) . Our results further support the latest ATA guidelines and warrant the need of careful evaluation for the presence and degree of VI in thyroid cancer.
Our primary and subgroup analyses also indicate that the presence of VI in DTCs is an independent and adverse risk factor on DTC patients' survival ( Table 3) . The significant overall estimate of HR for DSS is mostly attributable to the PTC population. When we separate into each histologic subgroup, there are heterogeneities in pooled results regarding impact of VI on DSS. The presence of VI is only associated with a significantly unfavorable effect on DSS in PTC patients, but this effect is not significant in FTC patients (Table 3) . The different criteria in diagnosis of PTC and FTC might be an appropriate explanation for this difference. In previous years before the latest consensus regarding new term of 'non-invasive follicular thyroid neoplasm with papillarylike nuclear features (NIFTP)' (45), the diagnosis of PTC mostly relies on the characteristic nuclear features and many cases of non-invasive encapsulated follicular variant PTCs (FVPTC) might be included in PTC series in our study. Meanwhile, the presence of at least VI and/ or capsular invasion is required for the diagnosis of FTC. Hence, the survival of patients in group of PTCs without VI might be much better than patients in group of PTCs with VI and results in higher HR ratio in PTC subgroup. Kim et al. (8) found an association of VI with increased mortality rate in minimally invasive but not in widely invasive FTCs and suggested that MIFTC be separated into two groups according to the presence or absence of VI. This finding, however, was not found in other MIFTC series (32, 33) , and our pooled analysis could not establish a significant association between VI and poorer outcome in MIFTCs (Table 3) . Although our pooled analysis indicates an insignificant effect of VI on FTC patient's survival, the presence and extent of VI in FTCs do need to be carefully examined and reported in histopathological report due to its significant association with increased risk for tumor recurrence or persistence in FTCs.
The diagnosis of microscopic VI has been an ongoing controversy in surgical histopathology and it is an important criterion in the diagnosis of FTC (3). Classic criteria for diagnosis of microscopic VI have been well described previously (3, 46, 47) , and these strict criteria should be used for the diagnosis of VI on routine histopathological examination to avoid artifactual displacement of tumor cells (47) . Our study has a limitation that not all included studies reported or described the criteria for diagnosis of VI and it could raise heterogeneity among the included studies. Nonetheless, the significant heterogeneity among included studies of the overall effects are present in only a few of pooled results and the pooled results remain statistically significant following the sensitivity analysis, thus reflecting a good stability of our analyses. Another limitation is that all of included studies were retrospective studies so selection biases are inevitable.
To summarize, our current study demonstrated the prognostic importance of VI as a predictor of tumor recurrence in both PTCs and FTCs and its association with unfavorable patient outcomes in PTCs. The presence and extent of VI in DTCs should be considered an adverse prognostic factor and needs to be carefully assessed on histopathological examination for accurate risk stratification, management and follow-up.
Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/ EJE-17-0260.
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